NeuroMetrix

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. It focuses on the sale of medical equipment and consumables. Its products include DPNCheck, Quell, and ADVANCE system. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

NeuroMetrix reports Q2 revenue decline but shows promise in Quell line

NeuroMetrix faced revenue decline due to DPNCheck product line, offset by strong growth in the Quell product line.
Efficient cost management reflected in a solid gross margin rate of 64% and reduced operating expenses.
The company maintains a healthy financial position with significant working capital and liquid assets.
Strategic review aims to enhance shareholder value and explore new growth avenues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NeuroMetrix, Inc. engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.

WOBURN, Mass., Oct. 14, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2021 third quarter financial results before the opening of the market on October 21, 2021. The Company will host a conference call at 8:00 a.m., Eastern Time on October 21, 2021 to discuss its financial results as well as business developments affecting the Company.

NeuroMetrix, Inc. Announces Date for Third Quarter 2021 Financial Results Conference Call

The stock price of Neurometrix Inc (NASDAQ: NURO) increased by over 10% pre-market today. This is why it happened.

NURO Stock: Why It Increased Today

NeuroMetrix Inc (NASDAQ: NURO) submitted a De Novo request to the FDA for Quell as a prescription treatment for fibromyalgia symptoms in adults.  The Company received FDA Breakthrough Designation for this indication in July.

Why Are NeuroMetrix Shares Shining In Thursday Premarket?

WOBURN, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has submitted a De Novo request to the U.S. Food and Drug Administration (FDA) for Quell as a prescription treatment for the symptoms of fibromyalgia in adults. The Company received FDA Breakthrough Designation for this indication in July.

NeuroMetrix Announces Submission of FDA De Novo Request for Treatment of Fibromyalgia Symptoms with the Quell® Wearable Neuromodulation Device

WOBURN, Mass., Oct. 05, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has joined the Center to Stream Healthcare In Place (C2SHIP) as an industry partner.

NeuroMetrix Announces Participation in the Center to Stream Healthcare In Place (C2SHIP) as an Industry Partner

Bill.com

The stock market is usually not very exciting on the last day of the week. But some stocks still tend to stir things up a little bit.

These two stocks gained 30% and 80% on Friday: here's why

NeuroMetrix Inc (NASDAQ: NURO) shares are surging higher Friday on abnormally high volume amid an increase in retail investor interest around the low-float stock. The average session volume is just under 8 million.

What's Going On With NeuroMetrix Shares Today?

NuroMetrix Inc. (NASDAQ:NURO) shares are trading higher Friday after the company began seeing increased retail interest in the stock. The stock has been seeing above average volume the past couple of days and was trending on social media sites throughout the day.

NuroMetrix Pushes Higher Friday: What's Next?

NeuroMetrix (NURO) is rocketing higher on Friday as retail investors short-squeeze share of the medical device company's stock. The post NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Investors Send Shares Soaring appeared first on InvestorPlace.

NURO Stock: 9 Things to Know About NeuroMetrix as Meme Stock Investors Send Shares Soaring

The stock price of Neurometrix Inc (NASDAQ: NURO) increased by over 30% pre-market. This is why it happened.

NURO Stock: Over 30% Increase Pre-Market Explanation

NURO stock is an interesting opportunity for sure. But it may be best to wait for it to head back to single-digit prices before buying.

NeuroMetrix May Struggle to Stay at Double-Digit Prices

NURO stock received attention from Reddit, but it should interest investors because of its other positive characteristics. The post NueroMetrix Stock Looks Strong Following Its Positive Catalysts appeared first on InvestorPlace.

NueroMetrix Stock Looks Strong Following Its Positive Catalysts

It's true that NURO stock could be the target of a massive short squeeze, but NeuroMetrix's medical and financial progress is also notable. The post Try NeuroMetrix Stock for a Stake in Breakthrough Medical Technology appeared first on InvestorPlace.

Try NeuroMetrix Stock for a Stake in Breakthrough Medical Technology

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled “Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research. The article is available online at the journal website.

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

NeuroMetrix, Inc. (NURO) CEO Dr. Shai Gozani on Q2 2021 Results - Earnings Call Transcript

NeuroMetrix Inc (NASDAQ: NURO) is surging higher Thursday morning after the company announced better-than-expected financial results.  NeuroMetrix reported a second-quarter earnings loss of 13 cents per share, which was up from a loss of 28 cents per share in the second quarter of 2020.

Why NeuroMetrix Stock Is Soaring Today

The stock price of Neurometrix Inc (NASDAQ: NURO) increased by 107.17% yesterday. This is why it happened.

NURO Stock Increased 107.17%: Why It Happened

WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders.

NeuroMetrix Reports Q2 2021 Financial Results

NeuroMetrix (NASDAQ:NURO) shares are trading higher by 153% at $25.41 on continued upward momentum after the company announced that its Quell device has received Breakthrough Designation from the FDA for treating the symptoms of fibromyalgia in adults. NeuroMetrix is a commercial-stage healthcare company.

Why NeuroMetrix Shares Are Skyrocketing Today

Neurometrix Inc. (NASDAQ:NURO) shares flew higher Tuesday and Wednesday on continued momentum after the company announced its Quell device received Breakthrough Designation from the FDA for treating the symptoms of fibromyalgia in adults. The stock was trending throughout the day on social media sites such as StockTwits.

NeuroMetrix Stock Skyrockets On FDA Update: Technical Levels To Watch

NURO stock is continuing its price-doubling into today. Retail investors have caught wind of NURO short selling and flocked to buy in.

NURO Stock: Why Reddit Traders Are Targeting Red-Hot NeuroMetrix Today

The stock price of Neurometrix Inc (NASDAQ: NURO) increased 207.98% yesterday. This is why it happened.

NURO Stock Increased 207.98%: Why It Happened

Shares of NeuroMetrix Inc. rocketed 241% toward a two-year high on record volume, after the Massachusetts-based medical device company said its Quell transcutaneous electric nerve stimulator received "Breakthrough Designation" from the Food and Drug Administration to treat fibromyalgia symptoms in adults. Trading volume ballooned to 228.3 million shares, compared with the full-day average over the past 30 days of about 125,600 shares, to make the stock the biggest gainer and most actively traded on major U.S. exchanges.

NeuroMetrix stock more than triples on massive volume after fibromyalgia treatment gets FDA boost

Genius Brands

Dogecoin price drop: An opportunity for penny stocks? The post 4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Penny Stocks To Watch As Hedge Against Dogecoin Price Drop Today

The stock price of Neurometrix Inc (NASDAQ: NURO) increased by 173% during intraday trading. This is why it happened.

News for NeuroMetrix Stock (NURO)